- Molecular NameTrovafloxacin
- SynonymTrovafloxacin mesylate; TVFX
- Weight416.359
- Drugbank_IDDB00685
- ACS_NO147059-72-1
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.07
- pkaN/A
- LogD (pH=7, predicted)-2.05
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.8
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.58
- No.of HBond Donors3
- No.of HBond Acceptors7
- No.of Rotatable Bonds3
- TPSA99.76
- StatusFDA approved
- AdministrationOral, intravenous
- PharmacologyA broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV.
- Absorption_value88.0
- Absorption (description)Well-absorbed from the gastrointestinal tract after oral administration and does not depend on concomitant food intake.
- Caco_2N/A
- Bioavailability91.0
- Protein binding70.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolism Trovafloxacin is metabolized by conjugation (the role of cytochrome P450 oxidative metabolism of trovafloxacin is minimal). The major metabolites include the ester glucuronide, which appears in the urine (13% of the administered dose); and the N -acetyl metabolite, which appears in the feces and serum (9% and 2.5% of the administered dose, respectively). Other minor metabolites include diacid, hydroxycarboxylic acid, and sulfamate, which have been identified in both the feces and the urine in small amounts (< 4% of the administered dose).
- Half life9.1~12.2 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include convulsions, decreased activity, diarrhea, sleepiness, tremors, and/or vomiting.
- LD50 (rat)N/A
- LD50 (mouse)N/A